Circulating Dipeptidyl Peptidase Activity Is a Potential Biomarker for Inflammatory Bowel Disease
Open Access
- 1 January 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 13 (1) , e00452
Abstract
INTRODUCTION: Dipeptidyl peptidase (DPP)-4 is part of a larger family of proteases referred to as DPPs. DPP4 has been suggested as a possible biomarker for inflammatory bowel disease (IBD). Circulating DPP4 (cDPP4) enzyme activity was investigated as a potential biomarker for IBD. In addition, DPP enzyme activity and gene expression were quantified in colonic tissue of patients with IBD and non-IBD. METHODS: In study 1, DPP enzyme activity was quantified in plasma samples from 220 patients with IBD (Crohn's disease [CD] n = 130 and ulcerative colitis [UC] n = 90) and non-IBD controls (n = 26) using a colorimetric assay. In study 2, tissue and plasma samples were collected from 26 patients with IBD and 20 non-IBD controls. Plasma C-reactive protein (CRP) was quantified in all patients. Colonic DPP4, DPP8, DPP9, and fibroblast activation protein (FAP) gene expression was determined by quantitative polymerase chain reaction. cDPP and cFAP enzyme activity was also measured. Sensitivity and specificity were determined by receiver operating characteristic curve analysis. RESULTS: In study 1, total cDPP activity was found to differentiate patients with CD with active disease (n = 18) from those in remission (n = 19; sensitivity 78% and specificity 63%). In study 2, total cDPP and cFAP activity was 28% and 48% lower in patients with elevated CRP (>10 mg/L), respectively, compared with patients with normal CRP. Gene expression of DPP4, FAP, and DPP8 was also significantly higher in colonic biopsies from patients with IBD compared with non-IBD patients (P < 0.05). DISCUSSION: Our findings implicate the DPP enzyme family in intestinal inflammation and suggest future biomarker applications to differentiate the pathophysiological aspects of IBD.Keywords
This publication has 57 references indexed in Scilit:
- Serum CD26 is related to histopathological polyp traits and behaves as a marker for colorectal cancer and advanced adenomasBMC Cancer, 2010
- Inhibition of fibroblast activation protein and dipeptidylpeptidase 4 increases cartilage invasion by rheumatoid arthritis synovial fibroblastsArthritis & Rheumatism, 2010
- Nature of action of sitagliptin, the dipeptidyl peptidase-IV inhibitor in diabetic animalsIndian Journal of Pharmacology, 2010
- The In Vivo Expression of Dipeptidyl Peptidases 8 and 9Journal of Histochemistry & Cytochemistry, 2009
- Use of the noninvasive components of the mayo score to assess clinical response in Ulcerative ColitisInflammatory Bowel Diseases, 2008
- C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based studyGut, 2008
- The fundamental basis of inflammatory bowel diseaseJournal of Clinical Investigation, 2007
- Dipeptidyl peptidase IV and related enzymes in cell biology and liver disordersClinical Science, 2005
- Dipeptidyl Peptidase IV (DP IV, CD26) in Patients with Inflammatory Bowel DiseaseScandinavian Journal of Gastroenterology, 2001
- Expression of dipeptidyl peptidase IV in rat tissues is mainly regulated at the mRNA levelsExperimental Cell Research, 1989